BNP Paribas Financial Markets Sells 402,852 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

BNP Paribas Financial Markets reduced its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 88.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 54,398 shares of the company's stock after selling 402,852 shares during the quarter. BNP Paribas Financial Markets' holdings in Amneal Pharmaceuticals were worth $453,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the business. Bank of New York Mellon Corp grew its stake in shares of Amneal Pharmaceuticals by 20.7% in the second quarter. Bank of New York Mellon Corp now owns 751,403 shares of the company's stock worth $4,771,000 after acquiring an additional 128,772 shares during the period. Acadian Asset Management LLC grew its position in shares of Amneal Pharmaceuticals by 701.8% in the 2nd quarter. Acadian Asset Management LLC now owns 811,853 shares of the company's stock worth $5,148,000 after buying an additional 710,598 shares during the last quarter. Jackson Creek Investment Advisors LLC purchased a new position in shares of Amneal Pharmaceuticals in the 2nd quarter worth approximately $1,027,000. Nisa Investment Advisors LLC boosted its stake in Amneal Pharmaceuticals by 3,279.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 228,917 shares of the company's stock worth $1,454,000 after purchasing an additional 222,144 shares in the last quarter. Finally, Rubric Capital Management LP lifted its stake in Amneal Pharmaceuticals by 12.4% during the 2nd quarter. Rubric Capital Management LP now owns 10,721,778 shares of the company's stock valued at $68,083,000 after acquiring an additional 1,179,830 shares during the period. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently issued reports on AMRX. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from an "underweight" rating to a "neutral" rating and set a $9.00 target price for the company in a report on Friday, September 6th. StockNews.com raised shares of Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Monday, November 11th. Truist Financial lifted their price objective on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a "buy" rating in a research report on Wednesday, October 2nd. Finally, Piper Sandler boosted their target price on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an "overweight" rating in a research report on Monday, November 11th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $10.00.

Insider Transactions at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, SVP Jason B. Daly sold 43,657 shares of the company's stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $8.61, for a total value of $375,886.77. Following the sale, the senior vice president now owns 13,665 shares in the company, valued at $117,655.65. This represents a 76.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 26.56% of the stock is currently owned by corporate insiders.

Amneal Pharmaceuticals Price Performance

Shares of Amneal Pharmaceuticals stock traded down $0.09 during midday trading on Friday, hitting $7.83. 735,063 shares of the company were exchanged, compared to its average volume of 1,384,085. The firm has a market cap of $2.43 billion, a P/E ratio of -11.51 and a beta of 1.12. Amneal Pharmaceuticals, Inc. has a 52 week low of $4.74 and a 52 week high of $9.48. The firm has a 50 day simple moving average of $8.49 and a 200-day simple moving average of $7.90.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.